tetano
Editor, Senior Moderator
Case Rep Nephrol Dial
. 2022 Mar 21;12(1):44-49.
doi: 10.1159/000521981. eCollection Jan-Apr 2022.
De novo Minimal Change Disease in an Adolescent after Pfizer-BioNTech COVID-19 Vaccination: A Case Report
Eva Pella[SUP] 1 [/SUP], Pantelis A Sarafidis[SUP] 1 [/SUP], Maria-Eleni Alexandrou[SUP] 1 [/SUP], Maria Stangou[SUP] 1 [/SUP], Christina Nikolaidou[SUP] 2 [/SUP], Dimitrios Kosmidis[SUP] 3 [/SUP], Aikaterini Papagianni[SUP] 1 [/SUP]
Affiliations
Abstract
This is the first report in an adolescent of minimal change disease (MCD) after the first injection of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech) with complete remission following steroid treatment. An 18-year-old white male with no prior medical history complained of gastrointestinal symptoms 11 days after his vaccination. Ascites and lower extremity edema were observed a few days later. He was admitted to a hospital as laboratory testing revealed proteinuria of 10.5 g/24 h, normal creatinine levels, and serum albumin of 1.8 g/dL, confirming the presence of nephrotic syndrome. Immunology and serology tests were unremarkable. A diagnostic kidney biopsy showed no significant glomerular or tubular abnormalities in light microscopy with negative immunofluorescence. Treatment with methylprednisolone 48 mg daily was initiated. A week after discharge, proteinuria declined to 1.2 g/24 h, and edema had disappeared, and 6 weeks later, complete remission was evident. As COVID-19 vaccination has been associated with the development of de novo and relapsing MCD, and this case provides additional support for this possible correlation.
Keywords: Coronavirus disease 2019; Minimal change disease; Nephrotic syndrome; mRNA-based coronavirus disease 2019 vaccine.
. 2022 Mar 21;12(1):44-49.
doi: 10.1159/000521981. eCollection Jan-Apr 2022.
De novo Minimal Change Disease in an Adolescent after Pfizer-BioNTech COVID-19 Vaccination: A Case Report
Eva Pella[SUP] 1 [/SUP], Pantelis A Sarafidis[SUP] 1 [/SUP], Maria-Eleni Alexandrou[SUP] 1 [/SUP], Maria Stangou[SUP] 1 [/SUP], Christina Nikolaidou[SUP] 2 [/SUP], Dimitrios Kosmidis[SUP] 3 [/SUP], Aikaterini Papagianni[SUP] 1 [/SUP]
Affiliations
- PMID: 35611026
- PMCID: PMC9082176
- DOI: 10.1159/000521981
Abstract
This is the first report in an adolescent of minimal change disease (MCD) after the first injection of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech) with complete remission following steroid treatment. An 18-year-old white male with no prior medical history complained of gastrointestinal symptoms 11 days after his vaccination. Ascites and lower extremity edema were observed a few days later. He was admitted to a hospital as laboratory testing revealed proteinuria of 10.5 g/24 h, normal creatinine levels, and serum albumin of 1.8 g/dL, confirming the presence of nephrotic syndrome. Immunology and serology tests were unremarkable. A diagnostic kidney biopsy showed no significant glomerular or tubular abnormalities in light microscopy with negative immunofluorescence. Treatment with methylprednisolone 48 mg daily was initiated. A week after discharge, proteinuria declined to 1.2 g/24 h, and edema had disappeared, and 6 weeks later, complete remission was evident. As COVID-19 vaccination has been associated with the development of de novo and relapsing MCD, and this case provides additional support for this possible correlation.
Keywords: Coronavirus disease 2019; Minimal change disease; Nephrotic syndrome; mRNA-based coronavirus disease 2019 vaccine.